Profitable companies and non-Profitable Biotech companies (rising stars) have developed innovative drugs for treatment of chronic and non chronic diseases. In the next five years the distinction between mature biotech companies and large global pharma is likely to disappear as investment in R&D and acquisition start delivering and Market Cap match the large global pharma. Dividend and consolidation could be the future drivers and continue to attract long term investors. Optimism prevails around the future of this sector as a whole which was reflected in the unprecedented rally in shares in 2012.
This trend continued in the next five years driven by launch of Innovative drugs catering to unmet needs in Alzheimer’s, HCV, osteoporosis, RA, Psoriasis, MS, Dyslipidemia, Cystic fibrosis, Cancer and orphan diseases. Drug approvals and label expansion of existing portfolio of launched drugs and data from late stage pipeline drugs should maintain the growth momentum and investors interest.
The early part of the previous decade (2010-20) was spent recovering from the big acquisitions made by this sector but followed by the exercising of some restrain for similar large acquisitions as investors wanted to see the returns reflected in the top-line and EPS. However in- licensing of early or mid stage compounds or small acquisitions continued since the Rising Stars kept throwing the bait by taking risks and innovate using novel technology platforms or validating novel targets for treating diseases.
Patent expiry impact was also modest as majority had “not so easy to copy” biologics and other drugs in their portfolio. They, however were not complacent and were not leaving any stones unturned to meet the challenges as well as exploring emerging market opportunities with local partners. Favorable regulatory environment finally saw biosimilar mAbs entry in regulated markets The optimism of biosimilar players is reflected in the maturing pipeline. Para IV Filing from other generic players continues to pour leaving room for surprises and volatility.
Moving forward the sector should see a strategic rise of the digital mindset and further adoption of transformative and augumentative technologies. While mergers & acquisitions can still expect a sharper focus despite being more traditional, external innovation should result in a meaningful shift in culture through innovative and creative partnerships with both new entrants and less traditional companies.
There will be an increasing demand for even more transparency and disclosure and a need for real relationship-driven partnerships will encroach across all sector stakeholders including regulators, patients, advocacy groups and also to outsourcing players critical to the supply chain. Data will be a dominating force behind new revenue models and crucial to understanding and delivering an exceptional patient experience. Pricing will continue to exert much pressure, increasing access to drugs, growth of gene and cell therapies, and uncertain trade policies will further change the dynamics of the market.
Industry News
- Researchers realize hydrogen formation by contact electrification of water microdroplets and its regulationby Bioengineer on April 18, 2024 at 3:16 pm
Direct utilization of water as a source of hydrogen atoms and molecules is fundamental to the evolution of the ecosystem and industry. However, liquid water is an unfavorable electron donor for forming these hydrogen species due to its redox inertness. Credit: JACS Direct utilization of water as a source of hydrogen atoms and molecules is
- Aston University researchers to use AI to help Ghanaian farmers monitor crops in real timeby Bioengineer on April 18, 2024 at 3:12 pm
Aston University researchers are to use AI to help increase the number and range of different crops grown in Ghana by developing real time monitoring systems. Credit: Tropical Growers Aston University is to help increase crop production in Ghana The University has entered a knowledge transfer partnership (KTP) with Tropical Growers, a Ghanaian fruit and vegetable
- Drawing a line back to the origin of lifeby Bioengineer on April 18, 2024 at 3:10 pm
It has long been debated how the seemingly fortuitous conditions for life arose in nature, with many hypothesises reaching dead ends. However, researchers at the University of Cambridge have now modelled how these conditions could occur, producing the necessary ingredients for life in substantial quantities. Credit: Oliver Shorttle Scientists in Cambridge University suggest molecules, vital
- Vertex inches closer to acute pain market with FDA application acceptanceby gmasson on April 18, 2024 at 2:33 pm
Vertex inches closer to acute pain market with FDA application acceptance gmasson Thu, 04/18/2024 - 10:33
- AACR: Biotechs emerge frostbitten from 'nuclear winter,' ready to show why they fought for survivalby aarmstrong on April 18, 2024 at 2:27 pm
AACR: Biotechs emerge frostbitten from 'nuclear winter,' ready to show why they fought for survival aarmstrong Thu, 04/18/2024 - 10:27
- Scientists experimentally observe current-driven antiskyrmion slidingby Bioengineer on April 18, 2024 at 2:22 pm
Prof. ZHANG Ying’s group from the Institute of Physics of the Chinese Academy of Sciences (CAS), in collaboration with domestic universities and the Los Alamos National Laboratory in the United States, has experimentally observed current-driven antiskyrmion sliding. Credit: Institute of Physics Prof. ZHANG Ying’s group from the Institute of Physics of the Chinese Academy of Sciences (CAS), in collaboration with domestic universities
- Properties of new materials for microchips can now be measured wellby Bioengineer on April 18, 2024 at 2:18 pm
Making ever smaller and more powerful chips requires new ultrathin materials: 2D materials that are only 1 atom thick, or even just a couple of atoms. Think about graphene or ultra-thin silicon membrane for instance. Scientists at TU Delft have taken an important step in application of these materials: they can now measure important thermal properties
- Peptides on Interstellar Iceby Bioengineer on April 18, 2024 at 2:16 pm
Peptides are organic compounds that play a crucial role in many biological processes, for example, as enzymes. A research team led by Dr Serge Krasnokutski from the Astrophysics Laboratory at the Max Planck Institute for Astronomy at the University of Jena had already demonstrated that simple peptides can form on cosmic dust particles. However, it
- Dana-Farber Chief Scientific Officer, Kevin Haigis, PhD, elected as Fellow of the American Association for the Advancement of Scienceby Bioengineer on April 18, 2024 at 2:14 pm
Boston – Kevin Haigis, PhD, Chief Scientific Officer, Dana-Farber Cancer Institute, has been named Fellow of the American Association for the Advancement of Science (AAAS). Election as an AAAS Fellow is a distinguished lifetime honor bestowed upon AAAS members by their peers. Credit: Dana-Farber Cancer Institute Boston – Kevin Haigis, PhD, Chief Scientific Officer, Dana-Farber
- Computational biology pioneer Katie Pollard elected as AAAS fellowby Bioengineer on April 18, 2024 at 2:12 pm
SAN FRANCISCO—April 18, 2024—The American Association for the Advancement of Science (AAAS), one of the world’s largest general scientific societies, has elected Gladstone Senior Investigator Katie Pollard, PhD, into its new class of AAAS Fellows, a lifetime honor within the scientific community. Credit: Gladstone Institutes SAN FRANCISCO—April 18, 2024—The American Association for the Advancement of
- Obesity-induced cognitive decline: Role of brain oxidation and tocotrienolsby Bioengineer on April 18, 2024 at 2:11 pm
Obesity has become a pressing worldwide health issue, with rates steadily rising over recent decades. Beyond its well-documented associations with physical health issues, such as cardiovascular disease and diabetes, obesity has also been linked to cognitive decline, including conditions like Alzheimer’s disease and Parkinson’s disease. Understanding the complex mechanisms underlying this cognitive impairment is crucial
- Two U professors selected as AAAS fellowsby Bioengineer on April 18, 2024 at 2:10 pm
University of Utah Health professors Amy Barrios, PhD, and H. Joseph Yost, PhD, have been elected as Fellows of the American Association for the Advancement of Science (AAAS), a lifetime honor that celebrates their excellence in research and commitment to mentoring the next generation of scientists. Credit: Kristan Jacobsen Photography / University of Utah Health
- Four MD Anderson researchers elected AAAS Fellowsby Bioengineer on April 18, 2024 at 2:08 pm
HOUSTON ― In recognition of their significant achievements in the realm of cancer care and research, four researchers at The University of Texas MD Anderson Cancer Center have been elected fellows of the American Association for the Advancement of Science (AAAS). This prestigious distinction stands as one of the highest accolades within the scientific research
- Biopharma M&A more than doubled in the first quarter compared to the year prior: reportby mbayer on April 18, 2024 at 2:00 pm
Biopharma M&A more than doubled in the first quarter compared to the year prior: report mbayer Thu, 04/18/2024 - 10:00
- Can bismuth prevent oil leaks – (and save Norwegians billions)?by Bioengineer on April 18, 2024 at 1:08 pm
Over the next 25 years, as the world shifts away from fossil fuels, the oil and gas wells that have sustained the fossil fuel age will have to be plugged. Credit: Photo: Per A.D. Jynge/NTNU Over the next 25 years, as the world shifts away from fossil fuels, the oil and gas wells that have
- AbbVie-bound Cerevel reports phase 3 Parkinson's victory in early win for $8.7B dealby ntaylor on April 18, 2024 at 12:20 pm
AbbVie-bound Cerevel reports phase 3 Parkinson's victory in early win for $8.7B deal ntaylor Thu, 04/18/2024 - 08:20
- AI tool predicts responses to cancer therapy using information from each cell of the tumorby Bioengineer on April 18, 2024 at 9:10 am
With more than 200 types of cancer and every cancer individually unique, ongoing efforts to develop precision oncology treatments remain daunting. Most of the focus has been on developing genetic sequencing assays or analyses to identify mutations in cancer driver genes, then trying to match treatments that may work against those mutations. Credit: Anne Weston,
- 5 RNA editing companies you should know aboutby Willow Shah-Neville on April 18, 2024 at 8:00 am
Check out five RNA editing companies on a mission to find a safer alternative to traditional gene editing techniques. The post 5 RNA editing companies you should know about appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.
- New patent for Jazz Pharms drug XYREMby DrugPatentWatch – Make Better Decisions on April 18, 2024 at 4:12 am
Annual Drug Patent Expirations for XYREM Xyrem is a drug marketed by Jazz Pharms and is included in one NDA. It is available from three suppliers. There are seven patents… Source The post New patent for Jazz Pharms drug XYREM appeared first on Biotechblog.
- New patent for Beigene drug BRUKINSAby DrugPatentWatch – Make Better Decisions on April 18, 2024 at 4:12 am
Annual Drug Patent Expirations for BRUKINSA Brukinsa is a drug marketed by Beigene and is included in one NDA. It is available from one supplier. There are nine patents protecting… Source The post New patent for Beigene drug BRUKINSA appeared first on Biotechblog.
- Pharmaceutical companies with the most ‘New Patient Population’ drugsby DrugPatentWatch – Make Better Decisions on April 18, 2024 at 4:12 am
This chart shows the companies which have received the most New Patient Population exclusivities in the past five years. New Patient Populations are one of the categories for which the… Source The post Pharmaceutical companies with the most ‘New Patient Population’ drugs appeared first on Biotechblog.
- Recycling CFRP waste is a challenge, but we’ve found a way to make it workby Bioengineer on April 18, 2024 at 4:10 am
Carbon fiber reinforced plastics (CFRP) are lighter and stronger than metal and are used in a variety of industries, including aviation, aerospace, automotive, marine, and sporting goods. In recent years, it has also been applied to new industries such as air mobility, which has led to an increase in its use and a waste disposal
- With $290M in hand, newly emerged biotech Metsera thinks customizable combos are the future of obesity treatmentsby gmasson on April 17, 2024 at 10:07 pm
With $290M in hand, newly emerged biotech Metsera thinks customizable combos are the future of obesity treatments gmasson Wed, 04/17/2024 - 18:07
- Sanofi shrinks IGM antibody partnership amid pipeline reprioritizationby gmasson on April 17, 2024 at 2:34 pm
Sanofi shrinks IGM antibody partnership amid pipeline reprioritization gmasson Wed, 04/17/2024 - 10:34
- Small but mighty: The role of small-molecule drugs in disease treatmentby Willow Shah-Neville on April 17, 2024 at 1:00 pm
Find out more about small-molecule drugs, including how they work and what their advantages and disadvantages are. The post Small but mighty: The role of small-molecule drugs in disease treatment appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.
- Lilly's Prevail walks away from gene editing collab with Precisionby jwaldron on April 17, 2024 at 12:12 pm
Lilly's Prevail walks away from gene editing collab with Precision jwaldron Wed, 04/17/2024 - 08:12
- Sage burns Parkinson's bridge, flunking first of 4 midphase tests for key prospectby ntaylor on April 17, 2024 at 11:55 am
Sage burns Parkinson's bridge, flunking first of 4 midphase tests for key prospect ntaylor Wed, 04/17/2024 - 07:55
- Ultimovacs lays off 40% of staff to survive in wake of cancer vaccine's phase 2 failby jwaldron on April 17, 2024 at 10:56 am
Ultimovacs lays off 40% of staff to survive in wake of cancer vaccine's phase 2 fail jwaldron Wed, 04/17/2024 - 06:56
- Connect Biopharma uncouples from Pfizer by scrapping long-standing eczema pactby ntaylor on April 17, 2024 at 10:39 am
Connect Biopharma uncouples from Pfizer by scrapping long-standing eczema pact ntaylor Wed, 04/17/2024 - 06:39
- New patent for Horizon Therap drug RAVICTIby DrugPatentWatch – Make Better Decisions on April 17, 2024 at 4:12 am
Annual Drug Patent Expirations for RAVICTI Ravicti is a drug marketed by Horizon Therap Us and is included in one NDA. It is available from one supplier. There are fifteen… Source The post New patent for Horizon Therap drug RAVICTI appeared first on Biotechblog.
- New patent for Tolmar drug ELIGARD KITby DrugPatentWatch – Make Better Decisions on April 17, 2024 at 4:12 am
Annual Drug Patent Expirations for ELIGARD+KIT Eligard Kit is a drug marketed by Tolmar and is included in four NDAs. It is available from one supplier. There is one patent… Source The post New patent for Tolmar drug ELIGARD KIT appeared first on Biotechblog.
- New patent for Agepha Pharma drug LODOCOby DrugPatentWatch – Make Better Decisions on April 17, 2024 at 4:12 am
Annual Drug Patent Expirations for LODOCO Lodoco is a drug marketed by Agepha Pharma Fz and is included in one NDA. It is available from one supplier. There are eight… Source The post New patent for Agepha Pharma drug LODOCO appeared first on Biotechblog.
- Which pharmaceutical companies have the most pellets dosed drugs?by DrugPatentWatch – Make Better Decisions on April 17, 2024 at 4:12 am
This chart shows the pharmaceutical companies with the most pellets dosed drugs. For a different perspective, see the most popular dosage types. The companies with the most pellets dosed drugs… Source The post Which pharmaceutical companies have the most pellets dosed drugs? appeared first on Biotechblog.
- Pfizer's academic-partnered R&D unit is scrapped as part of cost-cutting measuresby mbayer on April 17, 2024 at 3:36 am
Pfizer's academic-partnered R&D unit is scrapped as part of cost-cutting measures mbayer Tue, 04/16/2024 - 23:36
- Lilly Alzheimer's med glides out of Leqembi's slipstream with FDA adcomm requestby aarmstrong on April 17, 2024 at 1:32 am
Lilly Alzheimer's med glides out of Leqembi's slipstream with FDA adcomm request aarmstrong Tue, 04/16/2024 - 21:32
- VC firm Canaan adds $100M-plus for biotech bets and tacks on a Pfizer vet to gauge early scienceby mbayer on April 16, 2024 at 10:28 pm
VC firm Canaan adds $100M-plus for biotech bets and tacks on a Pfizer vet to gauge early science mbayer Tue, 04/16/2024 - 18:28
- Takeda inks sweet $1.2B-plus deal with Kumquat for immuno-oncology programby gmasson on April 16, 2024 at 3:20 pm
Takeda inks sweet $1.2B-plus deal with Kumquat for immuno-oncology program gmasson Tue, 04/16/2024 - 11:20
- AI-Driven Drug Discovery: Transforming the Landscape of Pharmaceutical Researchby DrugPatentWatch on April 16, 2024 at 1:30 pm
The pharmaceutical industry in China is undergoing a significant transformation with the adoption of artificial intelligence (AI) technology. A recent study published in the Future Journal of Pharmaceutical Sciences evaluates… Source The post AI-Driven Drug Discovery: Transforming the Landscape of Pharmaceutical Research appeared first on Biotechblog.
- Cullinan rebrands, halts lymphoma trial to reflect autoimmune refocusby jwaldron on April 16, 2024 at 1:27 pm
Cullinan rebrands, halts lymphoma trial to reflect autoimmune refocus jwaldron Tue, 04/16/2024 - 09:27
- Seven biotech companies climbing their way up in Coloradoby Roohi Mariam Peter on April 16, 2024 at 1:00 pm
We take a look at seven biotechs in Colorado that have secured funding in recent years, to make headway with their pipeline candidates. The post Seven biotech companies climbing their way up in Colorado appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.
- New patent for Abbvie drug UBRELVYby DrugPatentWatch – Make Better Decisions on April 16, 2024 at 4:09 am
Annual Drug Patent Expirations for UBRELVY Ubrelvy is a drug marketed by Abbvie and is included in one NDA. It is available from one supplier. There are seven patents protecting… Source The post New patent for Abbvie drug UBRELVY appeared first on Biotechblog.
- Which pharmaceutical drugs have the most drug patents in Slovenia?by DrugPatentWatch – Make Better Decisions on April 16, 2024 at 4:09 am
This chart shows the drugs with the most patents in Slovenia. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.… Source The post Which pharmaceutical drugs have the most drug patents in Slovenia? appeared first on Biotechblog.
- Regeneron builds new venture arm with $500M commitment to invest in biotech and beyondby mbayer on April 15, 2024 at 2:01 pm
Regeneron builds new venture arm with $500M commitment to invest in biotech and beyond mbayer Mon, 04/15/2024 - 10:01
- Pulmocide exits OPERA with phase 2 evidence of antifungal safety and efficacyby ntaylor on April 15, 2024 at 1:42 pm
Pulmocide exits OPERA with phase 2 evidence of antifungal safety and efficacy ntaylor Mon, 04/15/2024 - 09:42
- Does the FDA need to tighten its grip on drug trials in the U.S.? by Roohi Mariam Peter on April 15, 2024 at 1:00 pm
Studies suggest that the FDA has been less rigorous with its drug approval standards. We looked at the current state of the approval process. The post Does the FDA need to tighten its grip on drug trials in the U.S.? appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.
- Neumora's schizophrenia drug faces FDA hold over convulsions in rabbitsby jwaldron on April 15, 2024 at 12:00 pm
Neumora's schizophrenia drug faces FDA hold over convulsions in rabbits jwaldron Mon, 04/15/2024 - 08:00
- MaaT, eyeing 2026 launch for microbiome therapy, posts 18-month data in aGvHDby jwaldron on April 15, 2024 at 9:03 am
MaaT, eyeing 2026 launch for microbiome therapy, posts 18-month data in aGvHD jwaldron Mon, 04/15/2024 - 05:03
- Genentech axes Adaptimmune cell therapy deal as it presses ahead with staff cutsby gmasson on April 12, 2024 at 3:07 pm
Genentech axes Adaptimmune cell therapy deal as it presses ahead with staff cuts gmasson Fri, 04/12/2024 - 11:07
- Portage Biotech hints at potential closure as it halts programs, hunts for strategic optionsby mbayer on April 12, 2024 at 2:33 pm
Portage Biotech hints at potential closure as it halts programs, hunts for strategic options mbayer Fri, 04/12/2024 - 10:33
- Enlivex defends sepsis data that sank stock, shifting focus from mortality to subgroup analysisby ntaylor on April 12, 2024 at 1:31 pm
Enlivex defends sepsis data that sank stock, shifting focus from mortality to subgroup analysis ntaylor Fri, 04/12/2024 - 09:31
- 6 biotechnology universities in the US nurturing tomorrow’s trailblazersby Willow Shah-Neville on April 12, 2024 at 1:00 pm
Discover the top biotechnology universities in the US offering cutting-edge programs that are helping students find a career in biotech. The post 6 biotechnology universities in the US nurturing tomorrow’s trailblazers appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.
- Redefining chronic pain treatmentby Jim Cornall on April 12, 2024 at 8:00 am
Explore how Doloromics is reshaping chronic pain treatment using cutting-edge omics technologies. Listen to our podcast to learn more. The post Redefining chronic pain treatment appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.
- Seven companies leading the mRNA revolution in biotechnologyby Roohi Mariam Peter on April 11, 2024 at 8:00 am
Here are seven mRNA biotechs that have raised funds in recent years to push their candidates ahead through preclinical and clinical trials. The post Seven companies leading the mRNA revolution in biotechnology appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.
- Biotech naming trends bypass 'buzzwords and business speak' to build whimsical, memorable brandsby aarmstrong on April 10, 2024 at 3:06 pm
Biotech naming trends bypass 'buzzwords and business speak' to build whimsical, memorable brands aarmstrong Wed, 04/10/2024 - 11:06
- Silencing genes to cure diseases: an in-depth look at siRNAby Jules Adam on April 10, 2024 at 2:20 pm
Delve into the promissing and dynamic sector of siRNA technology, with new drug approvals and advancements in delivery methods. The post Silencing genes to cure diseases: an in-depth look at siRNA appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.
- Eight biotech companies you should know about in Austriaby Roohi Mariam Peter on April 9, 2024 at 1:00 pm
Here are eight Austrian biotech companies that have received funding in recent years to propel their pioneering innovations forward. The post Eight biotech companies you should know about in Austria appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.
- A wave of biotech layoffs: will the trend continue throughout 2024?by Willow Shah-Neville on April 8, 2024 at 1:00 pm
Thousands of jobs have been at risk over the past year due to mass layoffs by biotech companies across the globe. The post A wave of biotech layoffs: will the trend continue throughout 2024? appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.
- How to build a career as an investigator at the FDA?by Jules Adam on April 5, 2024 at 1:00 pm
Discover the role and implications of an FDA investigator, a career of high responsibility and challenges, from qualifications to application. The post How to build a career as an investigator at the FDA? appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.
- Colossal Biosciences’ 2028 goal: Bringing back the woolly mammothby Jim Cornall on April 5, 2024 at 8:00 am
Discover the pioneering work of Colossal Biosciences, a biotech firm leading the charge in de-extinction and endangered species preservation. The post Colossal Biosciences’ 2028 goal: Bringing back the woolly mammoth appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.
- Fierce Biotech Layoff Tracker 2024: Ultimovacs says goodbye to 40% of staff; Major pharmas turn to layoffsby gmasson on January 4, 2024 at 7:03 pm
Fierce Biotech Layoff Tracker 2024: Ultimovacs says goodbye to 40% of staff; Major pharmas turn to layoffs gmasson Thu, 01/04/2024 - 14:03
- Fierce Biotech Fundraising Tracker '24: Asher adds $55M, PureTech launches Seaport with $100Mby gmasson on January 2, 2024 at 5:12 pm
Fierce Biotech Fundraising Tracker '24: Asher adds $55M, PureTech launches Seaport with $100M gmasson Tue, 01/02/2024 - 12:12